• Mutation; HGNC; HGNC:952; BARD1; Simple; p.Trp218Ter (c.653G>A); ClinVar=VCV000482781; Zygosity=Unspecified (PubMed=25230021).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Unspecified (PubMed=25230021; DepMap=ACH-001628).
  

PubMed=3167863
Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A., Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Cancer Res. 48:6166-6172(1988)

PubMed=20581869; DOI=10.1038/onc.2010.245; PMCID=PMC2933510
Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T.J., Temple J., Langdon S.P., Huntsman D.G., Brenton J.D.
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Oncogene 29:4905-4913(2010)

PubMed=22183581; DOI=10.1002/path.3980
Ng C.K.Y., Cooke S.L., Howe K.L., Newman S., Xian J., Temple J., Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.
The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
J. Pathol. 226:703-712(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471; PMCID=PMC8714940
Huang D.-Q., Chowdhury S., Wang H., Savage S.R., Ivey R.G., Kennedy J.J., Whiteaker J.R., Lin C.-W., Hou X.-N., Oberg A.L., Larson M.C., Eskandari N., Delisi D.A., Gentile S., Huntoon C.J., Voytovich U.J., Shire Z.J., Yu Q., Gygi S.P., Hoofnagle A.N., Herbert Z.T., Lorentzen T.D., Calinawan A., Karnitz L.M., Weroha S.J., Kaufmann S.H., Zhang B., Wang P., Birrer M.J., Paulovich A.G.
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Cell Rep. Med. 2:100471.1-100471.32(2021)